138 related articles for article (PubMed ID: 30241878)
1. Health care utilization and expenditures among adults with rheumatoid arthritis using specialty pharmaceuticals.
Park T
Res Social Adm Pharm; 2019 Jun; 15(6):724-729. PubMed ID: 30241878
[TBL] [Abstract][Full Text] [Related]
2. The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients.
Shahabi A; Shafrin J; Zhao L; Green S; Curtice T; Marshall A; Paul D
J Med Econ; 2019 Apr; 22(4):350-358. PubMed ID: 30653389
[TBL] [Abstract][Full Text] [Related]
3. Medication adherence and cost-related medication non-adherence in patients with rheumatoid arthritis: A cross-sectional study.
Heidari P; Cross W; Weller C; Nazarinia M; Crawford K
Int J Rheum Dis; 2019 Apr; 22(4):555-566. PubMed ID: 30924291
[TBL] [Abstract][Full Text] [Related]
4. Shifting Cost-drivers of Health Care Expenditures in Inflammatory Bowel Disease.
Click B; Lopez R; Arrigain S; Schold J; Regueiro M; Rizk M
Inflamm Bowel Dis; 2020 Jul; 26(8):1268-1275. PubMed ID: 31671186
[TBL] [Abstract][Full Text] [Related]
5. Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey.
Kawatkar AA; Jacobsen SJ; Levy GD; Medhekar SS; Venkatasubramaniam KV; Herrinton LJ
Arthritis Care Res (Hoboken); 2012 Nov; 64(11):1649-56. PubMed ID: 22674912
[TBL] [Abstract][Full Text] [Related]
6. Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis.
Khanna R; Smith MJ
Clin Ther; 2007 Nov; 29(11):2456-67. PubMed ID: 18158087
[TBL] [Abstract][Full Text] [Related]
7. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis.
Weycker D; Yu EB; Woolley JM; Oster G
Clin Ther; 2005 May; 27(5):646-56. PubMed ID: 15978314
[TBL] [Abstract][Full Text] [Related]
8. Is rheumatoid arthritis care more costly when provided by rheumatologists compared with generalists?
Gabriel SE; Wagner JL; Zinsmeister AR; Scott CG; Luthra HS
Arthritis Rheum; 2001 Jul; 44(7):1504-14. PubMed ID: 11465700
[TBL] [Abstract][Full Text] [Related]
9. Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid Arthritis.
Baser O; Ganguli A; Roy S; Xie L; Cifaldi M
Clin Ther; 2015 Jul; 37(7):1454-65. PubMed ID: 25999184
[TBL] [Abstract][Full Text] [Related]
10. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
[TBL] [Abstract][Full Text] [Related]
11. Impact of Medicare Part D for Medicare-age adults with arthritis: prescription use, prescription expenditures, and medical spending from 2005 to 2008.
Cheng LI; Rascati KL
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1423-9. PubMed ID: 22508663
[TBL] [Abstract][Full Text] [Related]
12. Health Care Use and Spending of Pediatric Patients With an Intellectual or Developmental Disability.
Kim J; Stevens P; Carbone PS; Jones KB
Med Care; 2020 May; 58(5):468-473. PubMed ID: 31934953
[TBL] [Abstract][Full Text] [Related]
13. Comparing Medical Ecology, Utilization, and Expenditures Between 1996-1997 and 2011-2012.
Johansen ME
Ann Fam Med; 2017 Jul; 15(4):313-321. PubMed ID: 28694266
[TBL] [Abstract][Full Text] [Related]
14. Estimation of direct cost of managing rheumatoid arthritis treatment to Pakistani patients using real-world follow-up data.
Naqvi AA; Hassali MA; Naqvi SBS; Kachela B; Khan I
Int J Rheum Dis; 2020 Mar; 23(3):325-333. PubMed ID: 31880102
[TBL] [Abstract][Full Text] [Related]
15. Canadian estimates of health care utilization costs for rheumatoid arthritis patients with and without therapy with biologic agents.
Ohinmaa AE; Thanh NX; Barnabe C; Martin L; Russell AS; Barr SG; Maksymowych WP
Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1319-27. PubMed ID: 24470178
[TBL] [Abstract][Full Text] [Related]
16. Wide difference in biologics usage and expenditure for the treatment of patients with rheumatoid arthritis in each prefecture in Japan analyzed using "National Database of Health Insurance Claims and Specific Health Checkups of Japan".
Kamata Y; Minota S
Rheumatol Int; 2018 Apr; 38(4):663-668. PubMed ID: 29204683
[TBL] [Abstract][Full Text] [Related]
17. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
Polinski JM; Mohr PE; Johnson L
Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
[TBL] [Abstract][Full Text] [Related]
18. Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: A 1-year mirror-image study using a national claims database.
Chen KC; Wu CH; Tang CH; Huang KC
PLoS One; 2018; 13(7):e0200758. PubMed ID: 30020997
[TBL] [Abstract][Full Text] [Related]
19. Cost-related medication nonadherence in older patients with rheumatoid arthritis.
Harrold LR; Briesacher BA; Peterson D; Beard A; Madden J; Zhang F; Gurwitz JH; Soumerai SB
J Rheumatol; 2013 Feb; 40(2):137-43. PubMed ID: 23322458
[TBL] [Abstract][Full Text] [Related]
20. Do out-of-pocket costs affect medication adherence in adults with rheumatoid arthritis? A systematic review.
Heidari P; Cross W; Crawford K
Semin Arthritis Rheum; 2018 Aug; 48(1):12-21. PubMed ID: 29496225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
